ProQR Therapeutics N.V.(PRQR)

$1.70—

Chart

ProQR Therapeutics N.V.(PRQR)

NASDAQ

$1.70—

Chart Studio

PRQR(PRQR)

PRQR

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.14

Aug 6, 2026 · Reports before open

Revenue Estimate

$5M

Analyst Sentiment

Wall St. Consensus

Buy

12 analysts·Moderate coverage

Score

11 Buy (92%)1 Hold (8%)0 Sell (0%)

Rating Breakdown

Strong Buy

18%

Buy

1083%

Hold

18%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.00

+76.5%

Consensus

$3.00

+76.5%

Bull

$3.00

+76.5%

12-Month Target Range12 analysts

$3.00$3.00$3.00

Current $1.70Consensus

Current Price

$1.70

Upside to Consensus

$1.30

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+34.90%

EPS—

FY2028

Rev+138.29%

EPS—

FY2029

Rev+55.34%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$13M	$18M	$43M	$67M	$142M
Low	$12M	$11M	$25M	$39M	$82M
High	$16M	$25M	$55M	$86M	$182M
EBITDA Avg	$-13M	$-18M	$-43M	$-67M	$-142M
Low	$-16M	$-25M	$-55M	$-86M	$-182M
High	$-12M	$-11M	$-25M	$-39M	$-82M
EBIT Avg	$-13M	$-18M	$-43M	$-67M	$-142M
Low	$-16M	$-25M	$-55M	$-86M	$-182M
High	$-12M	$-11M	$-25M	$-39M	$-82M
Net Income Avg	$-51M	$-63M	$-44M	$-42M	$-15M
Low	$-61M	$-74M	$-70M	$-57M	$-21M
High	$-36M	$-37M	$9M	$-19M	$-7M
EPS Avg	$-0.46	$-0.50	$-0.35	$-0.40	$-0.15
Low	$-0.58	$-0.70	$-0.66	$-0.54	$-0.20
High	$-0.35	$-0.35	$0.08	$-0.18	$-0.07
Analysts (Rev / EPS)	5 / 4	5 / 4	3 / 4	2 / 2	1 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$4M	$4M	$3M	$2M	$1M	$1M
Low	$4M	$4M	$3M	$2M	$1M	$1M
High	$4M	$5M	$4M	$3M	$2M	$2M
EBITDA Avg	$-4M	$-4M	$-3M	$-2M	$-1M	$-1M
Low	$-4M	$-5M	$-4M	$-3M	$-2M	$-2M
High	$-4M	$-4M	$-3M	$-2M	$-1M	$-1M
EBIT Avg	$-4M	$-4M	$-3M	$-2M	$-1M	$-1M
Low	$-4M	$-5M	$-4M	$-3M	$-2M	$-2M
High	$-4M	$-4M	$-3M	$-2M	$-1M	$-1M
Net Income Avg	$-11M	$-12M	$-13M	$-14M	$-15M	$-18M
Low	$-13M	$-14M	$-15M	$-16M	$-17M	$-21M
High	$-8M	$-10M	$-10M	$-11M	$-12M	$-14M
EPS Avg	$-0.10	$-0.12	$-0.12	$-0.13	$-0.14	$-0.17
Low	$-0.12	$-0.13	$-0.14	$-0.15	$-0.16	$-0.19
High	$-0.08	$-0.09	$-0.10	$-0.10	$-0.11	$-0.13
Analysts (Rev / EPS)	4 / 2	3 / 1	3 / 1	2 / 1	2 / 1	3 / 1

Earnings Surprises

Recent Analyst Actions

Jun 26, 2026Chardan Capital

ProQR Therapeutics price target lowered to $3 from $4 at Chardan

Target:$3.00

+91.7%from $1.56

Mar 14, 2024Loop Capital Markets

ProQR Therapeutics N.V. (PRQR) PT Raised to $2.50 at Chardan Capital Markets

Target:$2.50

+7.8%from $2.32

Dec 30, 2022Raymond James

ProQR Therapeutics (PRQR) Stock Gets A $5 Price Target

Target:$5.00

+48.4%from $3.37

Dec 22, 2022Cantor Fitzgerald

Cantor Fitzgerald Upgrades ProQR Therapeutics N.V. (PRQR) to Overweight

Target:$5.00

+85.2%from $2.70

Aug 12, 2022Chardan Capital

ProQR Therapeutics downgraded to Neutral from Buy at Chardan

Target:$2.00

+145.4%from $0.81

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance